Cardiff Oncology, Inc. (CRDF) - Quarterly EPS earnings growth

Official company branding of Cardiff Oncology Inc. (CRDF)

Cardiff Oncology, Inc. (CRDF) is focusing on the expansion of onvansertib in combination with baseline oncology therapy to capture market share. This chart of quarterly EPS provided by GURU.Markets confirms operational strength, where the 31.10 mark indicates the profit level. Research and development cover the treatment of lung, prostate, and colorectal tumors. Environmental policy is based on strict laboratory waste disposal and office eco-standards.

Cardiff Oncology (CRDF) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 11/17/2026

Analytical breakdowns for Cardiff Oncology, Inc.

- market value and analyst target forecast:
Fundamental company analysis:Cardiff Oncology Inc., CRDF
Manufactured product of Cardiff Oncology, Inc.

Cardiff Oncology, Inc. (CRDF) focuses on overcoming drug resistance through the development of a PLK1 inhibitor for the therapy of KRAS mutations. The metric is calculated as the percentage change in net income per share compared to the same quarter of the previous year. This indicator measures the efficiency of R&D asset monetization and the speed of business scaling. Understanding this trend protects against inflationary losses and emotional overpayment. By analyzing the growth rates of quarterly net income per share, an investor can objectively assess the market reaction to 10-Q reports.

Analysis of competing companies

Incyte Corporation (INCY) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share growth for the last 12 months HUTCHMED Corp|NUVB (nuvationbio.com) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months dayonebio.com (DAWN)|Year-over-year earnings per share growth for the last twelve months Monopar Corp (MNPR)|INBX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months I-Mab Inc. IMAB|Fennec - Year-over-year earnings per share growth for the last twelve months|HRTX - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Nuvectis Pharma, Inc.|CHRS: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Corbus Pharma CRBP|Year-over-year net earnings per share growth for the last 12 months BYSI|Earnings per share growth in annualized terms for the last twelve months BioAtla BCAB|Year-over-year net earnings per share growth for the last 12 months LIXT (Lixte Biotechnology)|CTXR (Citius Pharma) - Year-over-year earnings per one share growth for the last 12 months|Cellectar Biosciences - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months BLRX (BioLineRx)|Can-Fite BioPharma, Ltd. - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months APRE (aprea.com)|KZIA: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Silexion (SLXN)|Year-over-year earnings per share growth for the last twelve months nucana.com|CMRX: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth CYCC|Quarterly EPS earnings growth G1 Therapeutics Inc. (GTHX)|Year-over-year earnings per share growth for the last twelve months Kronos Bio Corp KRON|KTRA (Kintara Therapeutics, Inc.) - Year-over-year net earnings per share trend for the last twelve months|ONCT: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Portage Biotech Inc